Boston Sci's Watchman Gets Positive Medicare Coverage Policy
Executive Summary
CMS granted national coverage for left atrial appendage closure procedures to prevent stroke under more favorable conditions than what the Medicare agency had proposed in November. This is good news for Boston Scientific, which is ramping up marketing of its Watchman device.
You may also be interested in...
Medicare Drops Registry Requirement In ICD Coverage Policy And Adds 'Shared Decision-Making'
The new Medicare coverage policy for implantable cardioverter defibrillators, the first revision since 2005, incorporates MRI-compatible devices, tweaks some of the patient criteria, removes thenational registry requirement, and adds a new requirement for "shared decision-making" prior to implanting an ICD in certain patients so the patients understand their options.
HRS 2017: EBR's Leadless CRT Feasibility; Watchman Registry Data; A Novel AF Ablation Catheter From BW; And More Medtronic CRT Data
Results from "real-world" registries of established devices, along with encouraging early results from novel devices were among the highlights of Heart Rhythm 2017, the annual scientific sessions of the Heart Rhythm Society, held in Chicago May 10-13.
Starts & Stops: Boston Scientific Starts, Stops, And Finishes TAVR Trials
Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. This month's edition includes seven trial-terminations – not as many as last month, but more than usual – for a variety of reasons, including Boston Scientific's suspension of all its trials of the Lotus transcatheter aortic valve due to a manufacturing problem.